China's healthcare reforms are generating uncertainty for its domestic pharmaceutical market, writes Jon Zifferblatt.
Foreign investors need the wiles of a tigress as the government revisits the idea of private healthcare
If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshhot of what's ahead for Big Pharma in the country
A shakeout is ahead as China restructures its murky and insular system of drug distribution
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial